Head-to-head · WeighScore
Direct Meds vs Piper
The verdict
Too close to call — both grade 82/100 (B−).
Direct Meds and Piper land on the same WeighScore, so neither clears the other on our six graded dimensions. Piper sits one line higher on the board (#26 vs #27) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.
Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Direct Meds | Piper |
|---|---|---|
| WeighScore | 82/100 | 82/100 |
| Grade | B− | B− |
| Scorecard rank | #27 | #26 |
| Semaglutide | $179/mo | $135/mo |
| Tirzepatide | $224/mo | $199/mo |
| Coverage | Not publicly listed | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #27 · B−
Strengths
- Rare oral/sublingual option in addition to injectable
- All-inclusive pricing with no separate membership fee
- Both molecules — semaglutide and tirzepatide
- Intro promotional pricing near $147
Where it loses points
- Compounded only — not FDA-approved
- Pricing is company-stated, not independently live-verified
- Newer and somewhat ambiguous (operates across multiple domains)
- States served are not disclosed
Graded #26 · B−
Strengths
- $135 sema / $199 tirz
- All 50 states
- Both molecules
Where it loses points
- Not LegitScript-verified
- Injection-only
- Monitoring detail limited
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 31 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.